A therapeutic approach involving not only AXL inhibition, but pan-TAM RTK inhibition may therefore help to prevent, or at least delay, resistance to PI3K inhibitors and improve outcomes for HNSCC patients. Here, PIK3CA is linked to head and neck squamous cell carcinoma.